Search

Displaying results 1491 - 1500 of 4598 in total
  1. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

  2. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). … In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs.

  3. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.

    Mixtures: SK Advanced Relief Eye Drops
  4. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]

  5. Drug

    Aluminum chloride

    go.drugbank.com/drugs/DB11081
    ApprovedInvestigational

    In antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012].

  6. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with

  7. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    The usage of glaucoma by pilocarpine dates back to 1875.[A262041] … [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.

  8. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. … treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by

  9. Drug

    Uprifosbuvir

    go.drugbank.com/drugs/DB15206
    Investigational

    Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis … C Genotype (GT)1 and GT2 Infection (MK-3682-011)).

  10. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    [A177709] Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.